Visceral Pain Pipeline Review H1 2015 Market Research Report

DALLAS, March 27, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Visceral Pain - Pipeline Review, H1 2015" therapeutic market research report of 52 pages with latest updates, data and information to its online business intelligence library.

The report "Visceral Pain - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Visceral Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Visceral pain is a type of nociceptive pain that comes from the internal organs. Stretching, distension, or ischemia of the viscera may cause visceral pain. In cancer patients, visceral pain may be caused not only by direct tumor infiltration, but also by variable conditions such as constipation, radiation, or chemotherapy. Complete report available at http://www.rnrmarketresearch.com/visceral-pain-pipeline-review-h1-2015-market-report.html .

The report "Visceral Pain - Pipeline Review, H1 2015" also reviews key players involved in the therapeutic development for Visceral Pain and special features on late-stage and discontinued projects. Companies discussed in this report include Amorepacific Corporation, Astellas Pharma Inc., GIcare Pharma Inc, Grunenthal GmbH, Hydra Biosciences, Inc., Nektar Therapeutics, Neurim Pharmaceuticals Ltd, Trevena, Inc.

Drug Profiles discussed in this report include ASP-7663, GIC-1001, GIC-1002, HC-030031, NeuP-12, NKTR-195, PAC-14028, piromelatine, RO-656570, Small Molecule to Block Nav1.9 Channel for Pain, Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder, TRV-250, URB-937. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314357 . (This is a premium report priced at US$2000 for a single user License.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The scope of the report ranges from global therapeutic landscape of Visceral Pain to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Explore more reports on Pain Management at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/pain-management .

More reports on Pain Management:

Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation

The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research's analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

Moderate Pain - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects. Companies discussed in this report include A. Menarini Industrie Farmaceutiche Riunite Srl, Acura Pharmaceuticals, Inc., Egalet Corporation, KemPharm, Inc., Laboratorios Del Dr. Esteve S.A., Lumosa Therapeutics Co., Ltd., Nektar Therapeutics, Pain Therapeutics, Inc., Pfizer Inc., Relmada Therapeutics, Inc., Trevena, Inc.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research